Indian Pharma: Moving from volume to value
Unravelling the deeper macro theme developing in the Indian pharma space. India got very good at making the same medicine cheaper than anyone else — and that is exactly the skill the market has stopped paying for. What every large Indian pharma company is quietly rebuilding around instead.
I’ve been going through a bunch of Indian pharma companies recently and one common theme keeps coming up.
India has traditionally been very good at one thing in pharma: making generic medicines at scale and at a low cost.
But there is a problem with that model. If 10 companies can make the same generic tablet, eventually everyone starts competing on price. And that is exactly what we are seeing in markets like the US.
So companies are now trying to move into areas where not everyone can compete — complex generics, injectables, inhalers, peptides, biosimilars, specialty drugs, CDMO.
Sounds like a lot of jargon, but the idea is actually simple: make things that are harder to make.
And this isn’t just something I’m concluding. Zydus itself talks about moving from volume-led generics towards higher-value specialty products.
How does the pharma value chain work?
To make this note more readable, let’s first understand how the pharma value chain works. At a very simple level:
A medicine starts with an API, or Active Pharmaceutical Ingredient. Think of the API as the actual chemical that produces the medical effect.
That API is then converted into a finished medicine. This finished medicine is called a formulation.
The formulation then goes through regulatory approvals before it can be sold in a particular market.
So broadly: API manufacturing, then formulation manufacturing, then regulatory approval, and finally the sale of the medicine.
Different Indian pharma companies participate at different points in this chain.
- Divi’s is primarily an API and custom-synthesis manufacturer.
- Cipla, Torrent, Lupin and Sun Pharma are much more focused on finished medicines.
- Laurus participates across APIs, formulations and increasingly CDMO (we’ll come to this later).
What exactly is a generic medicine?
That distinction becomes important when we understand where the industry is moving.
Suppose a global pharmaceutical company discovers a new medicine. It spends years on research, trials and regulatory approvals, and generally gets patent protection around that product.
Once the relevant patent protection expires, other pharmaceutical companies can manufacture equivalent versions of that medicine. Those are called generic drugs.
India became extremely successful at this business. Indian companies developed the capability to manufacture generic drugs cheaply and at enormous scale, and supply them across the world. This has been one of India’s biggest advantages in global pharma.
But there is a problem. If ten companies can manufacture the same generic tablet, eventually the competition becomes largely about price. More competitors enter. Customers negotiate harder. Prices fall. And margins can come under pressure.
Torrent explicitly highlights pricing pressure and price erosion in generic markets such as the US and Germany. Zydus similarly identifies intense generic competition as a risk, and says its response is to move up the value chain through complex products with higher entry barriers.
From simple generics to difficult-to-copy medicines
And this appears to be one of the most important shifts happening across Indian pharma today.
A normal generic could be a relatively straightforward tablet. A complex generic is still based on an existing medicine, but it is much harder to develop and manufacture. Examples include:
- inhalers
- complex injectables
- peptide products
- transdermal patches
- drug-device combinations
- long-acting formulations
Why does complexity matter? Because if a medicine is difficult to manufacture, develop and get approved, fewer companies may be capable of entering that market.
So companies are trying to move away from products where many manufacturers can compete mainly on price, towards products where technical capability, R&D and regulatory expertise create barriers to entry.
Zydus describes this transition very clearly. It says it is moving from volume-led generics towards innovation-driven, high-value specialty segments.
- Lupin is building a pipeline with 45+ injectables and 20+ inhalation products, and is also expanding into biosimilars and specialty products.
- Cipla is investing in respiratory medicines, peptide injectables, biosimilars, complex formulations and drug-device combinations.
- Torrent’s pipeline also includes complex generics, injectables, biologics, oncology and other differentiated products.
So even though these companies have different business models, the direction is similar: make products that are harder for competitors to replicate.
What are biosimilars?
There is another layer above traditional generics.
Many newer medicines are biological drugs, which are much more complicated than normal chemically manufactured medicines. The generic-like equivalent of a biologic is called a biosimilar.
These are significantly harder to develop and manufacture than a normal generic tablet. That is why companies such as Lupin, Zydus, Cipla and others are investing in this area.
Again, the attraction is similar: higher complexity, stronger regulatory requirements, fewer capable competitors.
Sun Pharma is taking this one step further
Most of the discussion so far has been about making increasingly difficult versions of existing medicines. Sun Pharma is also moving towards Innovative Medicines.
Here the company is increasingly participating in medicines that are more differentiated and closer to the traditional global innovative-pharma model. Sun says the contribution of branded generics and Innovative Medicines has steadily increased, reducing its dependence on more commoditised opportunities.
So Sun Pharma is effectively taking the value transition further: not only making more difficult generics, but increasing exposure to differentiated and innovative medicines.
The API manufacturing companies are moving up the value chain too
For companies such as Laurus and Divi’s, the shift looks different. They are not primarily trying to create brands that doctors prescribe. Their opportunity lies in becoming a more important partner to global pharmaceutical companies.
This is where CDMO becomes important. CDMO stands for Contract Development and Manufacturing Organisation.
Imagine a global pharma company develops a new drug. Instead of building every manufacturing capability internally, it can ask a company such as Laurus to help with:
- developing the manufacturing process
- producing material for clinical trials
- scaling manufacturing
- supplying the API
- eventually manufacturing commercial volumes
So there is a big difference between “sell me 10 tonnes of this API” and “work with me from the development stage and help manufacture this drug for the next several years”. The second relationship is deeper and much more technically involved. That is the CDMO opportunity.
Laurus’ Q1 FY27 numbers show how meaningful this shift has become. CDMO revenue grew 67% YoY and represented around 43% of total revenue. At the same time, revenue grew 29%, EBITDA grew 66% and EBITDA margin increased from 24.8% to 31.8%, with management attributing the improvement partly to favourable business and product mix.
Divi’s also saw a higher contribution from custom synthesis in Q1, with management noting somewhat better margins — although the company cautioned that quarterly mix can be lumpy.
So on the manufacturing side, the shift is essentially: from being a supplier to becoming a development and manufacturing partner.
Why is the industry making this shift now?
There appear to be a few structural reasons.
1. Traditional generics are getting increasingly competitive
This is probably the most basic driver. When many companies manufacture the same generic drug, pricing pressure becomes inevitable. Therefore companies increasingly need products where fewer competitors can enter.
That is why words such as complex, differentiated, limited competition, specialty and biologics keep appearing across these companies’ filings.
2. A large global patent-expiry cycle is coming
A large number of global drugs will lose patent protection over the coming years. Torrent highlights a significant patent-expiry opportunity, while broader industry estimates point to roughly $200 billion+ of branded-drug revenues facing loss of exclusivity by 2030.
When a drug loses exclusivity, generic or biosimilar manufacturers can potentially enter. The important difference this time is that many of the drugs losing exclusivity are increasingly more complicated products and biologics. So you are technically getting access to produce more complex medicine products when the patent expires.
So the opportunity is not simply “who can make the cheapest tablet?” It can increasingly become “who actually has the technical and regulatory capabilities to make this product?” That plays directly into the capabilities Indian pharma companies are currently building.
3. Chronic diseases are creating very large markets
The other major structural opportunity is the growing burden of diabetes, obesity, cardiovascular diseases, oncology, neurological diseases and other chronic illnesses. Torrent highlights increasing cardiovascular and metabolic disease burden, particularly across emerging markets.
GLP-1 drugs are a good current example.
- Torrent has launched Semaglutide in oral and injectable formats.
- Zydus launched three differentiated Semaglutide formulations in March 2026.
- Cipla has also entered obesity treatments through generic Liraglutide, while building peptide capabilities.
So GLP-1 is not the entire pharma theme. But it is a good example of how large chronic-disease markets, patent expiries and improving Indian manufacturing capabilities can come together.
4. Global pharma is outsourcing more work
Another important opportunity is manufacturing outsourcing. Instead of global pharma companies doing everything internally, parts of drug development and manufacturing are increasingly outsourced to specialist partners. That creates opportunities for Indian CDMO companies.
Laurus highlights rising outsourcing and increasing demand for end-to-end development and manufacturing services. Torrent also highlights supply-chain diversification and the China Plus One opportunity for Indian pharmaceutical manufacturing. Even Zydus has entered biologics CDMO through the acquisition of US manufacturing facilities.
So another part of the macro story is India trying to capture a greater share of global pharmaceutical development and manufacturing, not just generic drug sales.
What does all of this mean financially?
This is the most important part from an investing perspective.
It would be incorrect to say: higher-value medicine = automatically higher margin.
Complex products require substantially more R&D, capex, regulatory work, time and execution capability. Some products may also fail or face unexpected competition.
But if the strategy works, a company can potentially move towards fewer competitors, a better product mix, stronger pricing, better utilisation and higher margins.
Laurus already gives us one example where stronger CDMO contribution and better product mix have coincided with significant margin expansion. Cipla management has similarly said upcoming differentiated products carry healthy margins, and that product mix remains important for profitability.
The bigger Indian pharma story
For decades, India’s pharmaceutical advantage was largely low manufacturing cost, large scale and generic medicines.
The next stage companies appear to be trying to build towards is more value addition and complex manufacturing. And that is opening up opportunities across complex generics, inhalers, injectables, peptides, biosimilars, biologics, specialty medicines, Innovative Medicines and CDMO.
So the broader macro theme can perhaps be summed up in one line: Indian pharma is gradually moving from a volume-led industry towards a value-led industry, trying to capture more value from each medicine it develops or manufactures rather than simply producing more medicines.
And that’s where the company-level analysis becomes interesting. Because now the question isn’t just “which pharma company is growing fastest?”
It’s: which company is actually moving up the value chain, how much of its revenue is already coming from these higher-value areas, is that improving margins and returns, and how much of that opportunity is already reflected in the valuation?
9 min read